| Trademark Snap Shot Amendment & Mail Processing Stylesheet (Table presents the data on Amendment & Mail Processing Complete) |
|||
OVERVIEW |
|||
| SERIAL NUMBER | 88424870 | FILING DATE | 05/10/2019 |
| REG NUMBER | 0000000 | REG DATE | N/A |
| REGISTER | PRINCIPAL | MARK TYPE | TRADEMARK |
| INTL REG # | N/A | INTL REG DATE | N/A |
| TM ATTORNEY | BUTLER, MIDGE FAE |
L.O. ASSIGNED | 107 |
PUB INFORMATION |
|||
| RUN DATE | 05/28/2020 | ||
| PUB DATE | 10/08/2019 | ||
| STATUS | 688-NOTICE OF ALLOWANCE - ISSUED | ||
| STATUS DATE | 12/03/2019 | ||
| LITERAL MARK ELEMENT | CERECOR | ||
| DATE ABANDONED | N/A | DATE CANCELLED | N/A |
| SECTION 2F | NO | SECTION 2F IN PART | NO |
| SECTION 8 | NO | SECTION 8 IN PART | NO |
| SECTION 15 | NO | REPUB 12C | N/A |
| RENEWAL FILED | NO | RENEWAL DATE | N/A |
| DATE AMEND REG | N/A | ||
FILING BASIS |
|||||
| FILED BASIS | CURRENT BASIS | AMENDED BASIS | |||
| 1 (a) | NO | 1 (a) | NO | 1 (a) | NO |
| 1 (b) | YES | 1 (b) | YES | 1 (b) | NO |
| 44D | NO | 44D | NO | 44D | NO |
| 44E | NO | 44E | NO | 44E | NO |
| 66A | NO | 66A | NO | ||
| NO BASIS | NO | NO BASIS | NO | ||
MARK DATA |
|
| STANDARD CHARACTER MARK | YES |
| LITERAL MARK ELEMENT | CERECOR |
| MARK DRAWING CODE | 4-STANDARD CHARACTER MARK |
| COLOR DRAWING FLAG | NO |
CURRENT OWNER INFORMATION |
|
| PARTY TYPE | 20-OWNER AT PUBLICATION |
| NAME | Cerecor Inc. |
| ADDRESS | 373 Iverness Parkway Englewood, CO 80112 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |
GOODS AND SERVICES |
|
| INTERNATIONAL CLASS | 005 |
| DESCRIPTION TEXT | Pharmaceutical preparations for the prevention and treatment of disorders and diseases in or affecting the central nervous system; Pharmaceutical preparations for the treatment of the brain, central nervous system, and psychiatric and neurological diseases and disorders; Pharmaceutical preparations and substances for the prevention and treatment of major depressive disorder, mood disorder, psychosis, anxiety, epilepsy, sclerosis, porphyries, stroke, Huntington's disease, insomnia, Parkinson's disease, cognitive impairment; Pharmaceutical preparations for the treatment of ectoparasites, such as head lice; Steroids; Pharmaceutical preparations containing prednisolone for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculoskeletal system, the genitourinary system; Pharmaceutical preparations containing prednisolone for the treatment of inflammatory disorders; Pharmaceutical preparations containing prednisolone for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Medical delivery apparatus, namely, a valved holding chamber sold empty for use with metered dose inhalers; Cephalosporins; Antibiotics; Pharmaceutical preparations for the treatment of reflux, esophagitis, GERD (Gastro-Esophageal Reflux Disease), dyspepsia, heartburn, acid regurgitation, pyrosis, epigastric pain, irritative cough and dysphonia; Oral modified release, extended release, and/or sustained release pharmaceutical preparations for the drug carbinoxamine, a pharmaceutically acceptable salt thereof and/or carbinoxamine polistirex, intended for the treatment of seasonal and perennial allergic rhinitis, and other approved uses; Vitamin, mineral and fluoride preparations for human medical or nutritional uses; Nutritional preparation in the nature of nutritional supplement containing vitamins and fluoride; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulation of D-galactose for the treatment of phosphoglucomutase 1 (PGM1) deficiency (PGM1-CDG), oral formulation of D-mannose for the treatment of Mannose Phosphate Isomerase (MPI) deficiency (MPI-CDG), oral formulation of L-fucose for the treatment of Leukocyte Adhesion Deficiency Type II (LADII) (SLC35C1-CDG), nucleotide prodrug for the treatment of Deoxyguanosine Kinase (DGUOK) deficiency; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral formulations for the treatment of congenital disorders of glycosylation; Pharmaceutical products and treatments for pediatric onset and rare and orphan disorders, namely, oral nucleotide replacements for the treatment of Myelodysplastic Syndromes; Pharmaceutical preparations and substances for the treatment of neurogenic orthostatic hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy, and Pure Autonomic Failure; Transmembrane AMPA receptor regulatory proteins (TARPs) for use as anticonvulsant agents and to modulate neurotransmission in patients with epilepsy; Oral neuro-selective adjunctive medications; Selective kappa opioid receptor (KOR) antagonist for the treatment of major depressive disorder (MDD) and for substance use disorders |
GOODS AND SERVICES CLASSIFICATION |
|||||||
| INTERNATIONAL CLASS | 005 | FIRST USE DATE | NONE | FIRST USE IN COMMERCE DATE | NONE | CLASS STATUS | 6-ACTIVE |
MISCELLANEOUS INFORMATION/STATEMENTS |
|
| CHANGE IN REGISTRATION | NO |
| OWNER OF US REG NOS | 4822297 |
PROSECUTION HISTORY |
||||
| DATE | ENT CD | ENT TYPE | DESCRIPTION | ENT NUM |
| 05/27/2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 023 |
| 05/27/2020 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | 022 |
| 04/28/2020 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | 021 |
| 04/28/2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | 020 |
| 04/28/2020 | EWAF | I | TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | 019 |
| 04/28/2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 018 |
| 04/28/2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 017 |
| 04/28/2020 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | 016 |
| 12/03/2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 015 |
| 10/08/2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 014 |
| 10/08/2019 | PUBO | A | PUBLISHED FOR OPPOSITION | 013 |
| 09/18/2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 012 |
| 09/05/2019 | ALIE | A | ASSIGNED TO LIE | 011 |
| 09/02/2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | 010 |
| 08/30/2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | 009 |
| 08/30/2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | 008 |
| 08/30/2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | 007 |
| 08/01/2019 | GPRN | O | NOTIFICATION OF PRIORITY ACTION E-MAILED | 006 |
| 08/01/2019 | GPRA | F | PRIORITY ACTION E-MAILED | 005 |
| 08/01/2019 | CPRA | R | PRIORITY ACTION WRITTEN | 004 |
| 07/25/2019 | DOCK | D | ASSIGNED TO EXAMINER | 003 |
| 05/25/2019 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 002 |
| 05/14/2019 | NWAP | I | NEW APPLICATION ENTERED IN TRAM | 001 |
CURRENT CORRESPONDENCE INFORMATION |
|
| ATTORNEY | Jake D. Siciliano |
| CORRESPONDENCE ADDRESS | Jake D. Siciliano 8845 Rehco Road San Diego CA 92121 |
| DOMESTIC REPRESENTATIVE | NONE |
PRIOR OWNER INFORMATION |
|
| PARTY TYPE | 10-ORIGINAL APPLICANT |
| NAME | Cerecor Inc. |
| ADDRESS | 540 Gaither Road, Suite 400 Rockville, MD 20850 |
| ENTITY | 03-CORPORATION |
| CITIZENSHIP | Delaware |